Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AbbVie, abstinent, acamprosate, acetaldehyde, add, Alameda, alcohol, alcoholism, ANTABUSE, antagonist, arbaclofin, arriving, attainment, AUD, AZILECT, bank, Barr, Benckiser, benzodiazepine, BioPharma, blockage, blocker, borrow, byproduct, CAMPRAL, Capnia, capsule, characteristic, circulating, Clinton, compel, compelling, Computershare, confirmatory, Congressional, contest, COSENTYX, craving, cut, cyber, DAC, denying, dissolution, disulfiram, divested, divestment, doubt, drinking, DUOPA, edition, Embedded, Ernest, error, exacerbated, excitation, facilitate, FileNo, flexibility, footnote, forfeited, fractional, GABA, glutamate, great, hacker, harder, headache, heavy, home, HYP, indenture, Indivior, interpersonal, intoxication, King, lieu, logistical, lymphopenia, malfeasance, Manual, Mario, markedly, Mental, mesylate, naltrexone, network, NIAAA, nonstatutory, ocrelizumab, opioid, OTEZLA, PASI, pharmacodynamic, placement, pleasant, PLEGRIDY, pneumonia, proportion, Psychiatric, psychological, qualitative, quantitative, rasagiline, Reckitt, recreational, recurrent, refinance, repay, repurchase, repurchased, resign, resold, retrospective, REVIA, robust, Roche, Shareowner, social, sophistication, spent, sPGA, Static, strike, Subtopic, successor, takeover, termsubstantial, tildrakizumab, trustee, unbranded, understood, unpaid, upfront, verify, VIVITROL, washout, wholly, withheld
Removed:
abnormal, acquiror, Allergan, alleviation, Ashworth, backed, binding, botox, catheter, cerebral, chiral, College, complicated, confusion, contracture, coordination, cord, creating, crossed, dantrolene, David, debilitating, demonstration, diazepam, DPN, Duane, duodenum, elderly, excitatory, extremity, fluid, functioning, gastroesophageal, gel, GERD, GRS, Guilford, imbalance, implantable, infection, inherently, inhibitory, inMovement, intensity, interval, invasive, invented, isomer, isomeric, joining, Jon, light, Maryland, McKinsey, mixture, motion, muscle, negotiating, onabotulinumtoxin, palsy, par, pharmacy, portable, powerful, procedure, proven, pump, racemic, receptor, reflux, rental, Savello, sodium, SPA, spinal, spite, spouse, step, stretch, surgical, theExit, tizanidine, tone, treating, unusual, urinary, variance, younger
Filing tables
Filing exhibits
Related press release
XNPT similar filings
Filing view
External links
Exhibit 10.31
Executive Officer Compensation Information – 2015 Salaries and Target Bonus Percentages
The table below provides information regarding the annual base salaries and target bonus percentages for the Company’s executive officers currently employed by the Company for the 2015 performance period:
Named Executive Officer | 2015 Annual Base Salary | 2015 Target Bonus Percentage(1) | ||
Ronald W. Barrett, Ph.D. | $517,500 | 90% | ||
Chief Executive Officer | ||||
Vincent J. Angotti | $454,574 | 60% | ||
Executive Vice President, Chief Operating Officer | ||||
Gregory T. Bates, D.V.M. | $356,462 | 40% | ||
Senior Vice President of Regulatory Affairs and Quality | ||||
William G. Harris | $391,679 | 40% | ||
Senior Vice President of Finance and Chief Financial Officer | ||||
Richard K. Kim, M.D. | $401,500 | 40% | ||
Senior Vice President of Clinical Development and Medical Affairs and Chief Medical Officer |
| (1) | Represents a percentage of 2015 annual base salary pursuant to the terms and conditions of the XenoPort, Inc. Corporate Bonus Plan. |